[Rational screen of high kelimycin-producing strain by combined conventional mutagenesis and high-throughput screen method].
Wei Sheng Wu Xue Bao
; 53(7): 758-65, 2013 Jul 04.
Article
en Zh
| MEDLINE
| ID: mdl-24195383
ABSTRACT
UNLABELLED Kelimycin, is a new macrolide antibiotic drug obtained through genetic engineering approaches. With 4"-O-isovalerylspiramycins as the major components, was produced by genetically engineered Streptomyces spiramyceticus transformed with 4"-O-acyltransferase gene from S. mycarofaciens. OBJECTIVE:
Improve the efficiency of strain fermentation, to meet the needs of industrial production.METHODS:
The enhanced kelimycin-producing strain was obtained by applying various conventional mutagenesis approaches, and high-throughput screen methods, including protoplast mutagenesis by ultraviolet, mutagenesis by diethyl sulfate and UV-reactivation, valine content resistance screen and enrichment of improved strains. A strategy for positive mutant enrichment was developed after mutagenesis and before high-throughput screen.RESULTS:
Finally, the high-producing strain WSJ-1-7-49-133-82-18-43 was obtained and its potency in shake flask increased by 56% compared to the original strain. The potency in 500 L pilot fermenter increased by 61%.CONCLUSION:
This study shows that the screening industrial production strains can be enhanced effectively by combining multiple conventional mutagenesis and high-throughput screen methods.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Streptomyces
/
Espiramicina
/
Mutagénesis
/
Técnicas Genéticas
/
Antibacterianos
Tipo de estudio:
Evaluation_studies
Idioma:
Zh
Revista:
Wei Sheng Wu Xue Bao
Año:
2013
Tipo del documento:
Article
País de afiliación:
China